Enfusion (NYSE:ENFN) Price Target Raised to $11.50

Enfusion (NYSE:ENFN) had its price objective upped by Piper Sandler from $10.00 to $11.50 in a research report sent to investors on Monday,Benzinga reports. The brokerage currently has a neutral rating on the stock.

Separately, Stifel Nicolaus upped their target price on Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $10.25.

Enfusion Trading Up 0.6 %

ENFN opened at $10.58 on Monday. The stock has a market capitalization of $1.36 billion, a P/E ratio of 264.57, a PEG ratio of 3.98 and a beta of 0.97. The stock has a 50-day moving average price of $9.77 and a 200-day moving average price of $9.03. Enfusion has a 12-month low of $7.52 and a 12-month high of $11.38.

Insider Activity

In other news, COO Neal Pawar sold 21,801 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $10.03, for a total value of $218,664.03. Following the transaction, the chief operating officer now owns 1,143,544 shares in the company, valued at approximately $11,469,746.32. This trade represents a 1.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 36.44% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ENFN. Arizona State Retirement System purchased a new position in Enfusion during the 2nd quarter valued at $86,000. Harbor Capital Advisors Inc. increased its position in shares of Enfusion by 12.4% during the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after buying an additional 1,315 shares during the period. Belvedere Trading LLC bought a new position in Enfusion in the third quarter worth about $114,000. Paloma Partners Management Co purchased a new stake in Enfusion in the third quarter worth about $157,000. Finally, The Manufacturers Life Insurance Company boosted its position in Enfusion by 27.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock valued at $167,000 after acquiring an additional 4,239 shares in the last quarter. Hedge funds and other institutional investors own 81.05% of the company’s stock.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.